Clinical Trials
19
Active:3
Completed:10
Trial Phases
4 Phases
Phase 1:6
Phase 2:7
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (43.8%)Phase 1
6 (37.5%)Phase 3
2 (12.5%)Phase 4
1 (6.3%)A Non-interventional Cohort Safety Study of Patients With hATTR-PN
Recruiting
- Conditions
- Hereditary Transthyretin Amyloidosis With Polyneuropthy
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 240
- Registration Number
- NCT04850105
- Locations
- 🇪🇸
Study Centre, Madrid, Comunidad De Madrid, Spain
🇪🇸Study Center, Madrid, Spain
A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN
Phase 4
Terminated
- Conditions
- Hereditary Transthyretin Amyloidosis With Polyneuropthy
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT04306510
- Locations
- 🇨🇦
Study Center, Toronto, Ontario, Canada
TEGSEDI Pregnancy Surveillance Program
Not yet recruiting
- Conditions
- Hereditary Transthyretin-mediated Amyloidosis With PolyneropathyPregnancy
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04270058
- Locations
- 🇺🇸
TEGSEDI Pregnancy Coordinating Center, Morgantown, West Virginia, United States
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- Familial Chylomicronemia
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Akcea Therapeutics
- Registration Number
- NCT03544060
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT03514420
- Locations
- 🇺🇸
Clinical Site, Ann Arbor, Michigan, United States
- Prev
- 1
- 2
- 3
- Next
News
Catalyst Pharmaceuticals Appoints Dr. William Andrews as Chief Medical Officer to Lead Rare Disease Strategy
Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company.